Leveraging the company’s iPSC capabilities can provide insight into the earliest drivers of diseases such as Alzheimer’s, she explains, in contrast to conventional autopsy samples which typically only allow for study of end-stage pathophysiology. By studying the role of Tau in human cells, the company aims to advance a novel therapeutic into the clinic for multiple tauopathies, such as Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy.  In targeting the Complement cascade in the innate immune system, iPierian’s platform is being leveraged to “tease out specific mechanisms of chronic inflammation that occur in various brain disorders.”